Amalgamated Financial’s Arcturus Therapeutics ARCT Stock Holding History

Amalgamated Financial’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$69K	Buy	+2,542	New	+$64.9K	﹤0.01%	2272

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's ARCT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Arcturus Therapeutics (ARCT) in Q1 2022: 2,542 shares worth $69K. The stake represents ﹤0.01% of the portfolio and ranks #2272 among its holdings.

130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

Amalgamated Financial held 2,542 shares of Arcturus Therapeutics worth $69K as of Q1 2022.
Arcturus Therapeutics was a new Amalgamated Financial position in Q1 2022.
Arcturus Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2272 holding.
130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.